7 found
Order:
Disambiguations
Andrew W. Siegel [3]Andrew Siegel [2]Andrew M. Siegel [2]Andrew Walter Siegel [1]
  1. Public Stem Cell Banks: Considerations of Justice in Stem Cell Research and Therapy.Ruth R. Faden, Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Xiao-Jiang Gao, Mark Greene, John A. Hansen, Patricia A. King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel, Davor Solter, Sonia M. Suter, Catherine M. Verfaillie, LeRoy B. Walters & John D. Gearhart - 2003 - Hastings Center Report 33 (6):13-27.
    If stem cell-based therapies are developed, we will likely confront a difficult problem of justice: for biological reasons alone, the new therapies might benefit only a limited range of patients. In fact, they might benefit primarily white Americans, thereby exacerbating long-standing differences in health and health care.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   11 citations  
  2.  39
    The Moral Insignificance of Crossing Species Boundaries.Andrew W. Siegel - 2003 - American Journal of Bioethics 3 (3):33-34.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   8 citations  
  3.  52
    Safety Issues In Cell-Based Intervention Trials.Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter - 2003 - Fertility and Sterility 80 (5):1077-1085.
    We report on the deliberations of an interdisciplinary group of experts in science, law, and philosophy who convened to discuss novel ethical and policy challenges in stem cell research. In this report we discuss the ethical and policy implications of safety concerns in the transition from basic laboratory research to clinical applications of cell-based therapies derived from stem cells. Although many features of this transition from lab to clinic are common to other therapies, three aspects of stem cell biology pose (...)
    Direct download  
     
    Export citation  
     
    Bookmark   4 citations  
  4.  45
    Assessing Decision-Making Capacity: A Primer for the Development of Hospital Practice Guidelines.Andrew M. Siegel, Anna S. Barnwell & Dominic A. Sisti - 2014 - HEC Forum 26 (2):159-168.
    Decision making capacity (DMC) is a fundamental concept grounding the principle of respect for autonomy and the practice of obtaining informed consent. DMC must be determined and documented every time a patient undergoes a hospital procedure and for routine care when there is reason to believe decision making ability is compromised. In this paper we explore a path toward ethically informed development and implementation of a hospital policy related to DMC assessment. We begin with a review of the context of (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  5. Attitudes towards euthanasia and assisted suicide: A comparison between psychiatrists and other physicians.Tal Bergman Levy, Shlomi Azar, Ronen Huberfeld, Andrew M. Siegel & Rael D. Strous - 2012 - Bioethics 27 (7):402-408.
    Euthanasia and physician assisted-suicide are terms used to describe the process in which a doctor of a sick or disabled individual engages in an activity which directly or indirectly leads to their death. This behavior is engaged by the healthcare provider based on their humanistic desire to end suffering and pain. The psychiatrist's involvement may be requested in several distinct situations including evaluation of patient capacity when an appeal for euthanasia is requested on grounds of terminal somatic illness or when (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  6.  52
    Gamete Donor Consent and Human Embryonic Stem Cell Research.Andrew W. Siegel - 2015 - Kennedy Institute of Ethics Journal 25 (2):149-168.
    There is a lack of consensus on whether the derivation and use of human embryonic stem cells (hESCs) from embryos remaining after infertility treatment morally require the informed consent of third-party gamete donors who contributed to the creation of the embryos. The principal guidelines for oversight and funding of hESC research in the United States make minimal or no demands for consent from gamete donors. In this article, I consider the arguments supporting and opposing gamete donor consent for hESC research (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  7.  45
    Some doubts about in vitro eugenics as a human enhancement technology.Andrew W. Siegel - 2014 - Journal of Medical Ethics 40 (11):732-732.